Pathophysiologie ya cancer ya prostate ezali nini?
Pathophysiologie ya cancer ya prostate ezali kolobela ba mécanisme mpe ba processus oyo ememaka na bokono mpe na bokono oyo ezali kokola.
Cancer ya prostate ezali bokono ya mabe oyo ebimaka na baselile ya prostate, oyo ezali mwa eteni ya nzoto ya moke oyo ezali na lolenge ya noix oyo ezalaka na nse ya pisini ya mibali.
Prostate ebimisaka mai ya mobali oyo epesaka mai ya mobali mpe ememaka yango.
Ntina mpenza ya kanser ya prostate eyebani malamu te, kasi eyebani ete ezali na makambo mingi oyo ebakisaka likama ya kozwa maladi yango.
Yango ezali bongo mbula, libota, loposo, mpe ba mutation mosusu ya ba gènes.
Cancer ya prostate ezalaka mingi na mibali ya mibu ya kobuta, mingi na bango bazali na mibu koleka 65.
Longola yango, mibali oyo bazali na libota oyo ezali na bato oyo babɛlá kanser ya prostate, oyo bazali bato ya Afrika mpe ya Amerika, mpe oyo bankɔkɔ na bango bautá na bisanga ya Caraïbes, bazali na likama mingi ya kozwa maladi yango.
Pathophysiologie ya cancer ya prostate ezali na bokóli ya kozanga bokengi mpe bokabwani ya baselile na kati ya prostate.
Yango ekoki kosalema mpo na mbongwana ya ba gène oyo ememaka na kobakisama ya ba facteur ya bokóli to mpe na kozanga kosala ba gènes oyo ebundisaka maladi.
Ntango kanser ezali kokola, ekoki kokɔta na binama ya pembeni, lokola libale, na kati ya libumu, mpe na ba ganglion lymphatique.
Na bantango mosusu, baselile ya kanser ekoki kobima na kanser ya liboso mpe kopalangana na biteni mosusu ya nzoto na nzela ya makila to ya misisa ya makila, likambo yango ebengamaka métastase.
Soki kanser epanzani, ezalaka mpasi mpo na kosalisa yango.
Cancer ya prostate ekoki mpe kopusama na ba facteur ya hormones, mingimingi hormone androgène ya testostérone.
Testostérone ekoki kopesa nzela ete baselile ya kanser ya prostate ekola, mpe bankisi mingi oyo basalelaka mpo na kosalisa kanser ya prostate ezalaka mpo na kokitisa nivo ya hormone yango to kopekisa yango esala mosala na yango.
Na mokuse, maladi ya kanser ya prostate ezali na bokóli mpe bokabwani ya baselile oyo ezali na kati ya prostate, oyo ekoki kopusama na ba facteur ya génétique, ya hormones mpe ya ezingelo.
Koyeba ndenge maladi yango esalaka ezali na ntina mingi mpo na koyeba ndenge ya kosalisa yango malamu mpe kosalisa bato oyo bazali na kanser ya prostate.
Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.
Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.
Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.
Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.
Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.
['Koboya: makambo ya monganga']
['Site oyo ezali kaka mpo na koteya mpe koyebisa bato makambo ya monganga, kasi ezali te mpo na kopesa toli to toli ya monganga.']
['Makambo oyo ezali na site yango esengeli te kosalelama mpo na koyeba maladi to kosalisa yango, mpe baoyo balingi kozwa toli ya monganga basengeli kotuna yango epai ya monganga oyo ayebi mosala yango malamu.']
['Tosengi na yo oyeba ete réseau neuronal oyo epesaka biyano na mituna, ezalaka mpenza malamu te soki ezali na makambo ya mituya. Na ndakisa, motango ya bato oyo bazali na maladi moko boye.']
['Sololá ntango nyonso na monganga to na moto mosusu oyo ayebi kosalisa maladi na yo. Koboya toli ya monganga te to kozela te mpo otángi likambo moko na site oyo. Soki okanisi ete ozali na maladi oyo esengeli kosalisa yo nokinoki, bengá 911 to kende na lopitalo ya pene. Site oyo to ndenge oyo ozali kosalela yango ezali na boyokani te na monganga ná moto oyo azali kosalisa yo.']
["Kozanga ndingisa: droit d'auteur"]
['Mobeko ya Copyright ya Milenere ya 1998, 17 U.S.C. § 512 (DMCA) epesi nzela na bakomi ya mikanda oyo bakanisi ete biloko oyo ezali na Internet ezali kobebisa lotomo na bango na kolanda mibeko ya copyright ya Etats-Unis. ']
['Soki ondimi na motema malamu ete makambo to biloko oyo ezali na site Internet to na ba service na biso ezali kobuka mibeko na yo, yo (to moto oyo azali na mokumba ya kobatela yo) okoki kotindela biso mokanda mpo na kosɛnga ete tólongola makambo to biloko yango to tópekisa yo kokɔta na yango. ']
['Basengeli kotinda bansango na mokanda na nzela ya email (tala na "Kotindelana" mpo na adresse ya email). ']
['Mibeko ya DMCA esengi ete mokanda na yo ya kofunda mbeba ya copyright ezala na makambo oyo elandi: (1) kolimbola mosala oyo ezali na droit ya copyright oyo bazali kofunda ete ebebisami; (2) kolimbola makambo oyo bazali kofunda ete ebebisi mpe makambo oyo ekoki mpo na kosalisa biso na koyeba esika makambo yango ezali; (3) makambo ya kosolola na yo, ata mpe adrɛsi na yo, nimero ya telefone mpe adrɛsi ya e-mail; (4) mokanda oyo okomi ete ondimi na motema malamu ete makambo oyo ozali kofunda ete ebebisami epesami nzela te na nkolo ya droit ya copyright, to na agent na ye, to na mibeko nyonso; ']
['(5) mokanda oyo okomi, oyo okotya sinyatili na yango mpo na komonisa ete makambo oyo okomaki ezali solo mpe ete ozali na lotomo ya kolandela lotomo ya babimisi oyo bazali koloba ete ebebisami; ']
['mpe (6) sinyatili ya moto oyo azali na lotomo ya kosala yango to ya moto oyo azali na lotomo ya kosala na nkombo na ye. ']
['Soki otye makambo nyonso te oyo ezali awa na likolo, yango ekoki kosala ete likambo na yo eumela.']
['Ndenge ya kosolola']
['Tosengi otindela biso email na motuna to likanisi nyonso.']
What is pathophysiology of prostate cancer?
The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.
Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.
The prostate gland produces seminal fluid, which nourishes and transports sperm.
The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.
These include age, family history, race, and certain genetic mutations.
Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.
Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.
The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.
This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.
These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.
As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.
In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.
Once the cancer has spread, it can be more difficult to treat.
Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.
Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.
In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.
Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Na ntina na']
['BioMedLib esalelaka ba ordinateur oyo esalemi na masini (machine-learning algorithms) mpo na kobimisa mituna mpe biyano.']
['Tobandi na mikanda ya minganga 35 millions ya PubMed/Medline. Lisusu, ba pages ya RefinedWeb.']
